Jane Street Group LLC Decreases Position in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Jane Street Group LLC lowered its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 89.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,308 shares of the medical instruments supplier’s stock after selling 20,134 shares during the period. Jane Street Group LLC’s holdings in Mesa Laboratories were worth $300,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MLAB. Canada Pension Plan Investment Board acquired a new position in Mesa Laboratories in the 2nd quarter valued at $26,000. FMR LLC lifted its position in Mesa Laboratories by 34.1% during the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 100 shares during the period. Quantbot Technologies LP acquired a new stake in Mesa Laboratories in the 3rd quarter worth about $70,000. Sanctuary Advisors LLC purchased a new stake in Mesa Laboratories in the 2nd quarter valued at about $183,000. Finally, Berry Wealth Group LP purchased a new stake in Mesa Laboratories in the 3rd quarter valued at about $204,000. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Trading Up 2.2 %

NASDAQ:MLAB opened at $142.03 on Friday. Mesa Laboratories, Inc. has a one year low of $83.68 and a one year high of $147.34. The business’s 50-day simple moving average is $123.23 and its 200 day simple moving average is $119.76. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.51 and a current ratio of 0.70. The stock has a market cap of $771.36 million, a price-to-earnings ratio of -3.12 and a beta of 0.82.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, February 28th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.45%. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.40%.

Analysts Set New Price Targets

MLAB has been the topic of several research analyst reports. StockNews.com cut shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Evercore ISI lifted their price target on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st.

Insider Buying and Selling

In other Mesa Laboratories news, CEO Gary M. Owens sold 2,518 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the sale, the chief executive officer now owns 45,888 shares in the company, valued at $5,213,794.56. This represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 4.40% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.